Impax (IPXL) Jumps on IPX066 Outlook

Shares of Impax Laboratories Inc. (NASDAQ:IPXL) rocketed up by almost 16 percent, after announcing its phase III clinical study of the safety and efficacy of IPX066 for the treatment of Parkinson’s disease showed “statistically significant, positive” results.

The share price is the highest the company, which makes generic drugs, has reached since going public in 1995.

Impax closed Tuesday at $25.52, gaining $3.45, or 15.63 percent.